← Back to patent-cliff list
Samuraciclib
Tier C — Watch / tradeSamuraciclib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK7
Indications (approved)：Adenocarcinoma, Pancreatic cancer, 胰腺导管癌, 粘液腺癌, Breast cancer, Metastatic breast cancer, Solid tumour
Regional status
US
Phase II
2017-11-14
EU
Phase II
2017-11-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Samuraciclib?
Approved indications include: Adenocarcinoma, Pancreatic cancer, 胰腺导管癌, 粘液腺癌, Breast cancer, Metastatic breast cancer, Solid tumour.
When does the Samuraciclib patent expire?
No public expiry year is available for Samuraciclib yet; this page updates once verified.
How do I get a quote for Samuraciclib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09